Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

Author's Avatar
Jun 13, 2023

Reata+Pharmaceuticals%2C+Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company’s research and development functions.